Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 7
---
 (surgery to remove the bladder).                                                                                                                                                                                                                                                                                                                            |
| Priority ReviewUS     | MATTERHORNJuly 2025 | ●For the treatment of resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction cancers.                                                                                                                                                                                                                                                                                                                                                                                                                                            |

Tagrisso

| ApprovalJapan​    | LAURAMay 2025New disclosure | ●As maintenance therapy after definitive chemoradiation therapy in locally advanced and unresectableEGFRm NSCLC.                                                                                                                                                                                                                                                                             |
| Phase III readout | FLAURA2July 2025            | ●Positive high-level results from the final OS analysis of the FLAURA2 Phase III trial showedTagrissowith the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared toTagrissomonotherapy for patients with 1st-line locally advanced or metastaticEGFRm NSCLC. |

16

Orpathys

| ApprovalChina | SACHIJune 2025New disclosure | ●In combination withTagrissofor the treatment of patients with locally advanced or metastatic non-squamousEGFRm NSCLC with MET amplification who have progressed following EGFR tyrosine kinase inhibitor therapy. |

camizestrant

| Data presentationASCO | SERENA-6June 2025 | ●Positive results from the SERENA-6 Phase III trial showed that camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) reduced the risk of disease progression or death by 56% compared to standard-of-care treatment (HR 0.44; 95% CI 0.31-0.60; p<0.00001) as assessed by investigator compared to continuing standard-of-care treatment with an aromatase inhibitor in combination with a CDK4/6 inhibitor in the 1st-line treatment of patients with HR-positive, HER2-negative advanced breast cancer whose tumours have an emergentESR1mutation. Median PFS was 16.0 months for patients who switched to the camizestrant combination versus 9.2 months for the comparator arm. |

BioPharmaceuticals – CVRM baxdrostat

| Phase III readout | BaxHTNJuly 2025 | ●Positive high-level results from the BaxHTN